Analyst Terence Flynn of Morgan Stanley maintained a Hold rating on Johnson & Johnson (JNJ – Research Report), boosting the price target to $169.00.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Terence Flynn’s rating is based on a combination of factors that reflect both opportunities and challenges for Johnson & Johnson. The company’s recent quarterly performance was generally in line with expectations, with a slight beat in revenue and a reiterated EPS guidance, indicating stability in its financial outlook. However, the impact of tariffs, particularly from China, on the Medtech segment and potential future pharmaceutical tariffs pose risks that could affect supply chains and lead to shortages.
Additionally, while new product cycles are helping to offset declines in Stelara, there remains limited visibility on the full impact of these tariffs and other external factors. Johnson & Johnson’s commitment to significant investments in U.S. manufacturing and R&D is a positive sign for its long-term growth prospects. Nonetheless, these mixed factors contribute to the Hold rating, as the stock may not present significant upside potential in the near term.
Flynn covers the Healthcare sector, focusing on stocks such as BioNTech SE, Gilead Sciences, and Merck & Company. According to TipRanks, Flynn has an average return of 1.9% and a 50.00% success rate on recommended stocks.
In another report released today, Barclays also maintained a Hold rating on the stock with a $166.00 price target.